Study of SHR-2173 for primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You weigh at least 40 kg (about 88 lbs).
- A kidney biopsy has confirmed you have primary membranous nephropathy.
- Your kidney disease is not caused by another condition like lupus, hepatitis, or cancer.
- You have not needed dialysis in the past year, and you do not have a history of cancer or a recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called FKC289 for people with membranous nephropathy (a kidney disease) that has not improved or has returned after other treatments. It aims to see if the treatment is safe and helps reduce protein in the urine.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
This trial tests an experimental drug called YK012 for people with a serious type of kidney disease called primary membranous nephropathy. It aims to see if the drug is safe and helps when other treatments have stopped working.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.